Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

C2N Diagnostics

Request full access

Developing innovative diagnostics for Alzheimer's disease and related neurodegenerative conditions

St. Louis, United StatesFounded 2007Biotech & Life Sciences

About C2N Diagnostics

C2N Diagnostics is a company focused on the development and commercialization of diagnostics for neurodegenerative conditions, with a primary focus on Alzheimer's disease. The company's core offering is the Precivity™ portfolio of blood tests, including the PrecivityAD™ and PrecivityAD2™ assays. These tests are designed for individuals aged 55 and older who are experiencing cognitive impairment, providing a less invasive and more cost-effective alternative to traditional diagnostic methods like PET scans and cerebrospinal fluid analysis.

C2N's diagnostic approach is based on high-resolution mass spectrometry to measure the concentration of specific proteins and peptides in the blood, which are then analyzed using proprietary algorithms to predict the likelihood of Alzheimer's disease pathology. This technology aims to facilitate earlier and more accurate diagnosis, which is critical for timely intervention and management of the disease.

The company operates in the clinical diagnostics market and has secured partnerships to expand its reach, such as a multi-year agreement with Unilabs for the exclusive distribution of its Precivity tests in Europe. C2N has also achieved regulatory milestones, including medical device certification from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its PrecivityAD2 blood test. The company is also developing a more comprehensive Brain Health Panel to assess multiple indicators of Alzheimer's and other neurological disorders.

Source: Dealroom company data

At a glance

Status
Operational
Employees
112
Open positions
None listed
Dealroom signal
83.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology, Medical Devices
Sector
Biotechnology, Spinout, Biotech and Pharma, Woman Founder, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Mar 2025 $0 — Samsung Bioepis · Samsung BioLogics · Samsung Ventures ↗
LATE VCOther financing Sep 2024 $7M $75M Alzheimer's Drug Discovery Foundation ↗
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

C2N Diagnostics website traffic

Latest recorded traffic for C2N Diagnostics is 7.3K monthly website visits, up 32.7% over the last three months. C2N Diagnostics's team grew 31.8% over the past year.

Latest monthly visits7.3K 3-month web change+32.7% 1-year team growth+31.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

C2N Diagnostics in the St. Louis ecosystem

Live from Dealroom

The C2N Diagnostics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • GHR Foundation
  • Alzheimer's Drug Discovery Foundation

Series A1 investor entered at this stage

  • Eisai

Series B and later3 investors entered at this stage

  • Samsung Bioepis
  • Samsung BioLogics
  • Samsung Ventures

Other known investors1 additional known investor

  • Washington University in St. Louis
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See C2N Diagnostics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.